Key US Patent Granted on Antibodies Against GM-CSF to Treat Inflammatory Disorders

IP Position around MorphoSys's MOR103 Program Significantly Strengthened

27-Nov-2008 - Australia

MorphoSys AG and the University of Melbourne announced that the U.S. Patent & Trademark Office (USPTO) has confirmed that it will issue U.S. Patent No. 7,455,836, covering key uses of antibodies against GM-CSF. The patent stems from a provisional patent application filed in the USPTO in 2000 by the University of Melbourne. In 2007, MorphoSys signed an agreement with the University of Melbourne, providing MorphoSys with an exclusive license to this patent family. The claims of the patent are directed to methods of ameliorating the effects of inflammation by administering to a patient an antibody directed against GM-CSF.

Human cytokine GM-CSF (Granulocyte macrophage-colony stimulating factor) is the target molecule of MorphoSys's proprietary MOR103 antibody program for the treatment of rheumatoid arthritis (RA). MOR103 is the first fully human antibody against GM-CSF in clinical trials. The drug could offer an innovative treatment option for RA based on a mechanism of action distinct from anti-TNF and other competing approaches. In 2004, the market for biopharmaceuticals to treat RA amounted to US$ six billion worldwide and is expected to further increase to US$ 14 billion in 2009.

"This new patent provides us with broad protection for our proprietary antibody program MOR103 in the United States, which is by far the largest market for RA drugs", commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "Our patent portfolio around this promising antibody-based program now extends beyond the specific MOR103 lead antibody, itself, and we anticipate that MOR103 will find application in other inflammatory disorders as well."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Last viewed contents

DURAN Group launches anniversary campaign to celebrate 120 years of laboratory glassware

DURAN Group launches anniversary campaign to celebrate 120 years of laboratory glassware

MedMira Extends Market Reach into Southeast Asia with Contract for One Million HIV Tests - SE Asia Latest Target Market in Growing Global Distributor Network

SAFC and Novozymes Biopharma extend joint agreement for the exclusive distribution of LONGR3 growth factor

ARIUS Research Signs Anti-Cancer Antibody Discovery Deal with Takeda - Three-Year Collaboration to look for Novel Cancer Treatments

Amorfix announces Michael Sonnenreich as new director and establishment of a scientific advisory board

ALTANA AG: Sale of pharmaceuticals business to Nycomed - Purchase price of approx. EUR4.5 billion

MediGene and The Johns Hopkins University Sign Development Collaboration for First Vaccine Candidates from MediGene's AAVLP Platform - Examination of product candidates for the prevention of HPV-associated diseases

Lexicon Genetics Initiates Clinical Trials of LX1031 for Irritable Bowel Syndrome

AMRI promotes Richard A. Saffee to Vice President and General Manager of Large Scale Manufacturing

Market Opportunities Abound for Life Science Suppliers in Multi-Billion Dollar U.S. Market for Biodefense Research

MIT biologists find that restoring the gene for cancer protein p53 slows spread of advanced tumors

Enzo Biochem Granted European Patent For Displacer Technology To Treat Gene Abnormalities - Methodology Could Make Possible Modification or Corrections of Cell Mutations